Pharma seeks swift market access for innovative treatments amid evolving regulations, emphasizing collaboration and proactive planning for timely delivery of life-changing therapies.
Since there is still relatively limited precedence to cell and gene therapy (CGT) manufacturing, there are many opportunities for improvement, specifically in raw material and product supply chains.
Data-driven personalization, stakeholder engagement, and empathetic understanding of patient experiences are needed to optimize outcomes and improve healthcare journeys
There is a vital need to involve physicians, build trust in real-world evidence (RWE), and promote collaboration among stakeholders for improved patient care and research efficacy
With the increased use of healthcare technologies, leading to record volumes of data, pharma need to be strategic in extracting insights to drive their marketing strategy.
The landscape of hemophilia care has undergone a remarkable transformation in recent decades, marked by momentous advancements in treatment, shifting societal attitudes, and an expanding scope of advocacy efforts.